MRC Centre for Drug Safety Science

MRC Centre for Drug Safety Science
Name	MRC Centre for Drug Safety Science
Established	2012
Location	London, United Kingdom
Affiliation	Medical Research Council, King's College London
Director	David J. Lewis
Research field	Pharmacovigilance; Toxicology; Drug Safety

MRC Centre for Drug Safety Science

The MRC Centre for Drug Safety Science is a translational research centre based in London linked to Medical Research Council and King's College London. The centre pursues interdisciplinary work that connects laboratory toxicology, clinical pharmacology, and regulatory science to address adverse drug reactions, engaging with institutions such as National Institute for Health and Care Research, National Health Service (England), European Medicines Agency, World Health Organization and multiple academic and industry partners. The centre hosts scientists and clinicians collaborating with organizations including University College London, Imperial College London, University of Oxford, University of Cambridge, and Public Health England.

History

Founded in 2012, the centre grew from collaborations between Medical Research Council units and clinical departments at King's College London, evolving amid initiatives like the Francis Crick Institute formation and the expansion of translational hubs exemplified by NIHR Biomedical Research Centres. Early milestones included grant awards from Wellcome Trust, strategic alignment with Medical Research Council Clinical Trials Unit, and partnerships with the European Society of Clinical Pharmacology and Therapeutics and the Royal Society of Medicine. Leadership drew on expertise associated with figures and institutions such as Dame Sally Davies, Sir Mark Walport, Sir Paul Nurse, Anthony Fauci, and programs like the UK Clinical Research Network.

Research Focus and Programs

Research programs emphasize mechanisms of drug-induced liver injury, cardiotoxicity, cutaneous adverse drug reactions, and immune-mediated toxicity, linking to methodologies used at National Institute for Health (NIH), Food and Drug Administration, European Medicines Agency, European Directorate for the Quality of Medicines, and modeling approaches from Dana-Farber Cancer Institute and Massachusetts General Hospital. The centre integrates high-throughput screening techniques pioneered at Broad Institute, imaging modalities from Francis Crick Institute, and omics platforms developed with collaborators such as Wellcome Sanger Institute, European Molecular Biology Laboratory, and European Bioinformatics Institute. Programs have interfaces with initiatives like Human Cell Atlas, UK Biobank, 100,000 Genomes Project, and registries maintained by Office for National Statistics.

Clinical and Translational Activities

Clinical translation involves pharmacovigilance networks, adverse event reporting systems, and trial safety oversight linked to entities such as ClinicalTrials.gov, European Clinical Research Infrastructure Network, NHS Blood and Transplant, and specialist centres affiliated with Guy's and St Thomas' NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, and Royal Free London NHS Foundation Trust. The centre contributes to guidance used by National Institute for Health and Care Excellence, interacts with regulatory reviews at Medicines and Healthcare products Regulatory Agency, and informs policy dialogues involving European Commission and World Health Organization. Training programs align with curricula from Royal College of Physicians, Faculty of Pharmaceutical Medicine, and postgraduate schemes from University of Edinburgh and University of Glasgow.

Collaborations and Partnerships

Partnerships span academic, clinical, and industry stakeholders including AstraZeneca, GlaxoSmithKline, Pfizer, Roche, Novartis, Johnson & Johnson, Eli Lilly and Company, Bayer, Sanofi, Takeda Pharmaceutical Company Limited, and biotech firms connected to Cambridge Biomedical Campus and Harwell Science and Innovation Campus. International research links include Harvard University, Johns Hopkins University, Yale University, Karolinska Institutet, Max Planck Society, Institut Pasteur, University of Toronto, and Monash University. Collaborative consortia mentioned with Innovative Medicines Initiative and Horizon 2020 programs extend to networks like European Medicines Regulatory Network and Global Research Collaboration for Infectious Disease Preparedness.

Funding and Governance

Core funding sources have included grants from Medical Research Council, project awards from Wellcome Trust, program support from National Institute for Health Research, and collaborative contracts with industry partners such as GlaxoSmithKline and AstraZeneca. Governance involves academic oversight through King's College London boards, funder representation from Medical Research Council and NIHR, and ethical review with committees like those at Health Research Authority and institutional review boards associated with Guy's and St Thomas' NHS Foundation Trust. External advisory input has included experts from European Medicines Agency, Food and Drug Administration, and academics affiliated with University of California, San Francisco and Stanford University.

Facilities and Resources

Laboratory and clinical units occupy facilities co-located with King's College Hospital, providing access to biobanks comparable to UK Biobank and sequencing resources akin to Wellcome Sanger Institute. Core technologies include mass spectrometry platforms similar to those at EMBL-EBI, high-content screening facilities modeled on Broad Institute systems, and computational infrastructure paralleling resources at Alan Turing Institute and European Bioinformatics Institute. The centre leverages clinical trial units, patient registries linked to Clinical Practice Research Datalink, and imaging suites with equipment standards seen at Royal Brompton Hospital.

Notable Publications and Impact

The centre's outputs have been cited in regulatory reviews and guidelines from European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and World Health Organization. Publications appear in journals such as The Lancet, New England Journal of Medicine, Nature Medicine, Science Translational Medicine, British Medical Journal, Nature Communications, Clinical Pharmacology & Therapeutics, Journal of Hepatology, and European Heart Journal, and have influenced drug safety labeling reviewed by Food and Drug Administration panels and advisory committees. Impact extends to citation networks including research from Imperial College London, University College London, University of Oxford, Harvard Medical School, and policy documents produced by National Institute for Health and Care Excellence and Public Health England.

Category:Medical research institutes in the United Kingdom Category:Pharmacology research